Beximco Pharmaceuticals Limited (AIM:BXP)

Beximco Pharmaceuticals Balance Sheet

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	854.11	1,136	1,169	675.47	635.02
Short-Term Investments	369.37	166.25	108.07	112.83	70.79
Cash & Short-Term Investments	1,223	1,302	1,277	788.3	705.81
Cash Growth	-6.03%	1.97%	61.96%	11.69%	-28.85%
Accounts Receivable	3,462	3,370	2,963	2,726	3,089
Other Receivables	304.98	215.62	217.35	174.05	223.58
Receivables	3,767	3,586	3,180	2,900	3,312
Inventory	13,307	13,473	11,573	8,265	7,163
Prepaid Expenses	136.62	60.96	53.23	36.03	155.35
Other Current Assets	2,383	2,455	2,335	1,781	1,713
Total Current Assets	20,818	20,876	18,419	13,771	13,049
Property, Plant & Equipment	43,049	42,808	42,212	36,531	35,241
Long-Term Investments	20.97	20.97	23.36	16.59	3.75
Goodwill	674.57	674.57	674.57	546.69	546.69
Other Intangible Assets	4,721	4,721	4,730	1,381	1,276
Long-Term Deferred Tax Assets	60.89	56.51	88.64	-	-
Total Assets	69,344	69,157	66,148	52,246	50,119
Accounts Payable	1,402	1,618	1,373	769.2	575.01
Accrued Expenses	2,832	2,581	2,042	1,420	1,466
Short-Term Debt	2,997	6,621	6,851	5,023	7,398
Current Portion of Long-Term Debt	1,132	1,293	1,905	1,287	1,346
Current Portion of Leases	139.3	146.52	160.58	113.98	108.12
Current Income Taxes Payable	429.27	454.09	99.45	222.51	285.89
Current Unearned Revenue	80.24	149.41	110.41	298.4	12.39
Other Current Liabilities	551.38	401.5	193.85	214.81	165.61
Total Current Liabilities	9,562	13,265	12,736	9,350	11,358
Long-Term Debt	1,433	2,158	2,997	972.7	1,443
Long-Term Leases	324.72	393.12	456.76	234.02	208.86
Long-Term Deferred Tax Liabilities	2,575	2,550	2,537	1,990	2,168
Other Long-Term Liabilities	1,443	1,295	1,161	1,013	958.38
Total Liabilities	17,441	21,537	21,512	14,881	17,321
Common Stock	4,461	4,461	4,461	4,461	4,056
Additional Paid-In Capital	6,959	6,959	6,959	6,959	6,959
Retained Earnings	35,079	30,806	27,748	24,180	20,059
Comprehensive Income & Other	1,450	1,454	1,432	1,431	1,422
Total Common Equity	47,950	43,681	40,600	37,031	32,495
Minority Interest	3,953	3,939	4,036	334.31	302.33
Shareholders' Equity	51,903	47,620	44,636	37,365	32,797
Total Liabilities & Equity	69,344	69,157	66,148	52,246	50,119
Total Debt	6,025	10,612	12,371	7,631	10,504
Net Cash (Debt)	-4,802	-9,310	-11,094	-6,843	-9,798
Net Cash Per Share	-10.76	-20.87	-24.87	-15.34	-21.96
Filing Date Shares Outstanding	446.11	446.11	446.11	446.11	446.11
Total Common Shares Outstanding	446.11	446.11	446.11	446.11	446.11
Working Capital	11,256	7,611	5,683	4,421	1,691
Book Value Per Share	107.48	97.91	91.01	83.01	72.84
Tangible Book Value	42,555	38,285	35,196	35,103	30,673
Tangible Book Value Per Share	95.39	85.82	78.90	78.69	68.76
Land	7,892	7,892	-	4,068	4,068
Buildings	17,005	16,704	-	8,129	7,822
Machinery	33,219	31,733	-	18,663	17,542
Construction In Progress	1,938	1,847	-	16,507	15,789

Source: S&P Global Market Intelligence. Standard template. Financial Sources.